Iolyx Therapeutics releases phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

Published on May 29, 2025
According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.
Continue reading on website
Other news

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

May 29, 2025
Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

CooperCompanies Reports Second Quarter Revenue Growth, Updates Full Fiscal Year Guidance

May 30, 2025
SAN RAMON, Calif.—CooperCompanies (Nasdaq: COO), a medical device company, yesterday announced financial results for its fiscal second quarter ended April 30, 2025. In the quarter, CooperCompanies reported that revenue increased 6 percent year-over-year to $1,002.3 million. CooperVision (CVI) revenue was up 5 percent to $669.6 million, and CooperSurgical (CSI) revenue was up 8 percent to $332.7 mi